Please login to the form below

Not currently logged in
Email:
Password:

Crescendo Biologics

This page shows the latest Crescendo Biologics news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Summit's $12m lifeline, Biohaven's speech anxiety pill, Crescendo's Humabody progress

Daily Brief: Summit's $12m lifeline, Biohaven's speech anxiety pill, Crescendo's Humabody progress

Our highly productive relationship draws together Takeda’s deep oncology experience with Crescendo’s expertise in developing optimally configured Humabodies. ... Together we are fast progressing towards our goal of developing next generation, highly

Latest news

More from news
Approximately 2 fully matching, plus 0 partially matching documents found.

Latest Intelligence

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    targeting drugs from the likes of Crescendo Biologics and Pfizer, and Celldex’ CD27-targeting antibody varlilumab which is in phase II testing for various solid tumour types. ... Meanwhile, AbbVie and Johnson &Johnson have both struck deals this year

  • Japanese pharma pulls no punches with post-Brexit UK Japanese pharma pulls no punches with post-Brexit UK

    For example, in October, Takeda announced a cancer collaboration with Crescendo Biologics, which could be worth nearly $800m to the Cambridge-based biotech.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • Crescendo Biologics appoints Edward Stewart as chief business officer Crescendo Biologics appoints Edward Stewart as chief business officer

    He joins the Cambridge, UK-based firm from Merrimack Pharmaceuticals. Biopharmaceutical group Crescendo Biologics has appointed Edward Stewart as its new chief business officer. ... Peter Pack, CEO of Crescendo Biologics, said: “A strong and

  • Crescendo Biologics appoints CFO Crescendo Biologics appoints CFO

    Theodora Harold joins the drug discovery firm. Cambridge, UK-based Crescendo Biologics has appointed Theodora Harold as its new chief financial officer. ... Dr Peter Pack, chief executive officer of Crescendo Biologics, said: “Theo's appointment as

  • C4X Discovery appoints chief executive officer C4X Discovery appoints chief executive officer

    Since joining GlaxoSmithKline's research department in 1988, Dix has held a series of senior leadership positions including chief executive officer of Convergence Pharmaceuticals and chairman of both Crescendo Biologics and

  • Crescendo Biologics appoints Dr Kevin Johnson as chairman Crescendo Biologics appoints Dr Kevin Johnson as chairman

    Brings Cambridge, UKfirm experience from Pangenetics. Cambridge, UK-based biopharmaceutical company Crescendo Biologics has appointed Dr Kevin Johnson as non-executive chairman of the board of directors. ... He said: “Crescendo Biologics has a very

  • Crescendo Biologics appoints Peter Pack as CEO Crescendo Biologics appoints Peter Pack as CEO

    Launches new strategy in oncology R&D. Crescendo Biologics has appointed Dr Peter Pack as CEO who will help to oversee the company's new strategy. ... Crescendo is now shifting its focus to oncology with novel VH-based checkpoint modulators and humabody

More from appointments
Approximately 3 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Random42 Scientific Communication

Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...

Latest intelligence

London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
The Future of Pharma sales: fast forward to 2029
Change is inevitable, and necessary, for growth in business....
International Women's Day - 8 March 2019
International Women's Day has been celebrated since its inception in 1911. But how far have we come?...

Infographics